Protective Effects of Lysergol against Complete Freund Adjuvant-Induced Rheumatoid Arthritis in Rats

Background: Rheumatoid Arthritis (RA) is a rapidly developing autoimmune disease caused by self-destruction of the immune system, resulting in deformed joints and erosion of the bones. In the current study, we explored the anti-arthritic impact of Lysergol against the Complete Freund Adjuvant (CFA)-stimulated arthritis in rat model. Materials and Methods: Administration of CFA was performed for inducing arthritis and the animals were divided into 4 distinct groups. The rats then received Lysergol at a dose of 20 mg/kg. The body weight, paw swelling, arthritic index score, inflammatory cytokine levels and other inflammatory parameters were assessed along with the histopathological examination. CFA-stimulated arthritic animals treated with Lysergol substantially increased the body weight and reduced the paw swelling, organ index and arthritic index. Results: Lysergol-treated rats further suppressed the levels of inflammatory cytokines including TNF-alpha, IL-6, IL-10 and IL-1 beta. Lysergol treatment also decreased the levels of Prostaglandin E2 (PGE2), Nitric oxide and Thromboxane B2 (TXB2), as well as C-Reactive Protein (CRP) and Cyclic Citrullinated Peptide (CCP). Conclusion: The present investigation thus found that Lysergol may be an appropriate substitute to the currently available treatments for RA, since it exhibits a remarkable anti-inflammatory effect against CFA-stimulated arthritis in rodent models.